微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Dobutamine
Dobutamine

重症

关键词重症 药物 多巴酚丁胺

词汇介绍

拓展阅读

解析

dobutamine [dəu'bju:təmi:n]

释义   n. 多巴酚丁胺

例句   Dopamine and Dobutamine will not work well in this situation. Early use of Adrenaline is advisable and urgent discussion with a Level 3 Consultant should be undertaken.多巴胺和多巴酚丁胺在这种情况下不会起作用。建议尽早使用肾上腺素,并与三级顾问进行紧急讨论。

概述

多巴酚丁胺是多巴胺的衍生物制药,分子式:C18H23NO3,分子量:301.38,多巴酚丁胺能促进患者肾上腺素受体激动能力,尤其在患者内脏血管的治疗作用,能够提高患者内脏血管的可选择性扩张效果。临床应用的多巴酚丁胺是含有右旋多巴酚丁胺和左旋多巴酚丁胺的消旋体。   作用机制 多巴酚丁胺是一种选择性肾上腺素能受体兴奋剂,直接兴奋β1受体使心肌收缩力增加。Gillespie等提出,多巴酚丁胺可增强心肌梗塞、心功能减退的病人的

Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality复制标题

米力农与多巴酚丁胺在心脏手术患者中的比较: 一项关于死亡率的回顾性队列研究

发表时间:2018-02-26

影响因子:7.0

作者: Nielsen DV

期刊:Crit Care

The study provided no information on clinical outcomes. Earlier trials comparing the efficacy of early generation phosphodiesterase inhibitors (maranon and enoximone) with dobutamine similarly lack data on effect on major clinical outcomes . Recent meta-analyses of randomized clinical trials with milrinone for cardiac dysfunction conclude that the use of milrinone is neither to be recommended nor refuted due to risk of bias and random error in current evidence. None of the included studies in these meta-analyses used dobutamine as a single comparator. One study using network meta-analytic data including indirect comparisons suggested no big differences between milrinone and dobutamine in cardiac surgery. To date, the only randomized trial sufficiently powered to establish the safety and efficacy profile of milrinone was the OPTIME-CHF trial enrolling 951 patients with nonsurgical acute exacerbation of chronic heart failure. The results of this trial suggested that milrinone might be harmful in patients with ischemic heart failure with LVEF < 40%. However, data are difficult to interpret as the study allowed cointerventions with dobutamine in randomized patients .

译文

该研究未提供有关临床结果的信息。比较早期磷酸二酯酶抑制剂(马龙和依诺酮)与多巴酚丁胺的疗效的早期试验同样缺乏有关对主要临床结局的影响的数据。最近对米力农治疗心功能不全的随机临床试验进行的荟萃分析得出结论,由于当前证据存在偏倚和随机错误的风险,因此不建议也不反对使用米力农。在这些荟萃分析中,所有纳入研究均未使用多巴酚丁胺作为单一对照。 一项使用网络荟萃分析数据(包括间接比较)的研究表明,米力农和多巴酚丁胺在心脏手术中没有太大差异。迄今为止,唯一有能力确定米力农安全性和有效性的随机试验是OPTIME-CHF试验,该试验招募了951例非手术性慢性心力衰竭急性加重患者。该试验的结果表明,米力农可能对LVEF <40%的缺血性心力衰竭患者有害。然而,数据难以解释,因为该研究允许在随机分组的患者中与多巴酚丁胺共同干预。